Particle Sciences & Absorption Systems Form Relationship for Enhanced Services

Particle Sciences Inc. (PSI), a leading pharmaceutical CRO, and Absorption Systems, a leading provider of preclinical pharmacokinetic services, recently announced the two companies are working together to provide their clients with enhanced drug development services by integrating preclinical pharmacokinetic data into the dosage form development scheme.

“Particle Sciences has always had a methodical approach to drug product development,” said Robert Lee, PhD, Particle Sciences’ Vice President Pharmaceutical Development. “Dosage form design is best done when informed by the in vivo solubility, permeability, and metabolism of the drug. This is true for oral drug products as well as other routes of administration. Absorption Systems has put in place a scaled in vitro/ex vivo/in vivo approach to obtaining this data, which lends itself to our needs. For those clients who desire it, Particle Sciences can integrate this data stream into our drug product development plan. Ultimately, this should prove to be a cost-effective way to drive efficiency and minimize time to the clinic.”

“Our portfolio includes a number of physicochemical and biological tests that can make formulation development a more rational and efficient process,” added Chris Bode, PhD, Vice President Scientific & Corporate Communications at Absorption Systems. “Particle Sciences is a leader in drug formulation and manufacturing, and we are very pleased they are leveraging our toolset in their efforts. I believe this is consistent with their overall innovative and comprehensive approach to drug product development.”

Absorption Systems, founded in 1996, assists pharmaceutical and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs and medical devices. The company’s mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. The CellPort Technologies platform, a suite of human cell-based test systems for drug transporter characterization, exemplifies Absorption Systems’ commitment to innovation and is soon to be an industry assay standard for in vitro drug interaction assessment.

Particle Sciences is an integrated provider of drug development services, focusing on emulsions, gels, particulates, and drug/device combination products with additional specialized capabilities in topical and mucosal drug delivery. Through a full range of formulation, analytic, and manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.